Machida H, Ijichi K, Ohta A, Honda M, Niimura M
Biology Laboratory, Yamasa Shoyu Co., Ltd., Chiba.
Microbiol Immunol. 1990;34(11):959-65. doi: 10.1111/j.1348-0421.1990.tb01074.x.
1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and nine other antiherpesviral nucleoside analogues were compared for their potencies against four strains of varicella-zoster virus (VZV) on three different cell lines: HEL cells, Vero cells, and MS cells established from a human malignant schwannoma. In contrast to the activity against herpes simplex virus type 1 previously reported, BV-araU showed extremely marked antiviral activity against VZV even on Vero cells. ED50, 50% plaque reduction dose, of BV-araU for VZV was 0.20-3.1 and 0.14-0.63 ng/ml on Vero cells and on HEL cells, respectively. Potency of BV-araU on MS cells was similar to that on these cell lines. There was not significant variation in anti-VZV activities of other nucleoside analogues on these three different cell lines except a few combinations of VZV strain and test compound.
1-β-D-阿拉伯呋喃糖基-E-5-(2-溴乙烯基)尿嘧啶（BV-araU）和其他九种抗疱疹病毒核苷类似物在三种不同细胞系上针对四株水痘-带状疱疹病毒（VZV）的效力进行了比较：人胚肺成纤维细胞（HEL细胞）、非洲绿猴肾细胞（Vero细胞）以及源自人恶性神经鞘瘤的MS细胞。与先前报道的对1型单纯疱疹病毒的活性不同，BV-araU即使在Vero细胞上也对VZV表现出极其显著的抗病毒活性。BV-araU对VZV的半数有效剂量（ED50，即导致50%空斑减少的剂量）在Vero细胞上为0.20 - 3.1 ng/ml，在HEL细胞上为0.14 - 0.63 ng/ml。BV-araU在MS细胞上的效力与在这些细胞系上相似。除了少数VZV毒株与测试化合物的组合外，其他核苷类似物在这三种不同细胞系上的抗VZV活性没有显著差异。
